CN112438903A - 包含山梨糖醇或其混合物作为有效成分的皮肤刺激缓解及皮肤炎症缓解用化妆品组合物 - Google Patents
包含山梨糖醇或其混合物作为有效成分的皮肤刺激缓解及皮肤炎症缓解用化妆品组合物 Download PDFInfo
- Publication number
- CN112438903A CN112438903A CN202010331275.9A CN202010331275A CN112438903A CN 112438903 A CN112438903 A CN 112438903A CN 202010331275 A CN202010331275 A CN 202010331275A CN 112438903 A CN112438903 A CN 112438903A
- Authority
- CN
- China
- Prior art keywords
- skin
- sorbitol
- cosmetic composition
- inflammation
- skin irritation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 49
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 title claims abstract description 43
- 239000000600 sorbitol Substances 0.000 title claims abstract description 43
- 206010040880 Skin irritation Diseases 0.000 title claims abstract description 25
- 239000002537 cosmetic Substances 0.000 title claims abstract description 22
- 201000004624 Dermatitis Diseases 0.000 title claims abstract description 20
- 231100000475 skin irritation Toxicity 0.000 title claims description 19
- 230000036556 skin irritation Effects 0.000 title claims description 19
- 239000004480 active ingredient Substances 0.000 title claims description 9
- 230000009467 reduction Effects 0.000 title description 6
- SNPLKNRPJHDVJA-ZETCQYMHSA-N D-panthenol Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCCO SNPLKNRPJHDVJA-ZETCQYMHSA-N 0.000 claims abstract description 28
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 claims abstract description 25
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 claims abstract description 25
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 claims abstract description 25
- 230000000694 effects Effects 0.000 claims abstract description 19
- 230000014509 gene expression Effects 0.000 claims description 23
- 230000004054 inflammatory process Effects 0.000 claims description 21
- 102000004889 Interleukin-6 Human genes 0.000 claims description 16
- 108090001005 Interleukin-6 Proteins 0.000 claims description 16
- 206010015150 Erythema Diseases 0.000 claims description 13
- 102000004125 Interleukin-1alpha Human genes 0.000 claims description 13
- 108010082786 Interleukin-1alpha Proteins 0.000 claims description 13
- 229940100601 interleukin-6 Drugs 0.000 claims description 13
- 229940101267 panthenol Drugs 0.000 claims description 13
- 235000020957 pantothenol Nutrition 0.000 claims description 13
- 239000011619 pantothenol Substances 0.000 claims description 13
- 102000004127 Cytokines Human genes 0.000 claims description 12
- 108090000695 Cytokines Proteins 0.000 claims description 12
- 231100000321 erythema Toxicity 0.000 claims description 12
- 239000006071 cream Substances 0.000 claims description 9
- 230000000844 anti-bacterial effect Effects 0.000 claims description 6
- 239000000839 emulsion Substances 0.000 claims description 6
- 230000002401 inhibitory effect Effects 0.000 claims description 6
- 239000006210 lotion Substances 0.000 claims description 6
- 235000015097 nutrients Nutrition 0.000 claims description 6
- 230000002757 inflammatory effect Effects 0.000 claims description 5
- 230000003020 moisturizing effect Effects 0.000 claims description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 3
- 239000008269 hand cream Substances 0.000 claims description 2
- 239000000344 soap Substances 0.000 claims description 2
- 239000002552 dosage form Substances 0.000 claims 1
- 230000001624 sedative effect Effects 0.000 claims 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 abstract description 40
- 235000004866 D-panthenol Nutrition 0.000 abstract description 14
- 239000011703 D-panthenol Substances 0.000 abstract description 14
- 229960003949 dexpanthenol Drugs 0.000 abstract description 14
- 125000001475 halogen functional group Chemical group 0.000 abstract description 2
- 210000003491 skin Anatomy 0.000 description 21
- 206010061218 Inflammation Diseases 0.000 description 20
- 230000003110 anti-inflammatory effect Effects 0.000 description 18
- 230000001939 inductive effect Effects 0.000 description 12
- 239000002994 raw material Substances 0.000 description 11
- 239000000306 component Substances 0.000 description 8
- 210000002510 keratinocyte Anatomy 0.000 description 8
- 210000004027 cell Anatomy 0.000 description 7
- 241000191967 Staphylococcus aureus Species 0.000 description 5
- 230000007794 irritation Effects 0.000 description 5
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 4
- 239000000686 essence Substances 0.000 description 4
- 210000002540 macrophage Anatomy 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 3
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 3
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 3
- 239000002299 complementary DNA Substances 0.000 description 3
- 230000003013 cytotoxicity Effects 0.000 description 3
- 231100000135 cytotoxicity Toxicity 0.000 description 3
- 210000002865 immune cell Anatomy 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 239000007858 starting material Substances 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- 230000002195 synergetic effect Effects 0.000 description 3
- 229920001817 Agar Polymers 0.000 description 2
- 102000000589 Interleukin-1 Human genes 0.000 description 2
- 108010002352 Interleukin-1 Proteins 0.000 description 2
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 2
- QHOREGFPJWHMCU-HFEGYEGKSA-N OCCCNC([C@@H](O)C(C)(C)CO)=O.OCCCNC([C@@H](O)C(C)(C)CO)=O Chemical compound OCCCNC([C@@H](O)C(C)(C)CO)=O.OCCCNC([C@@H](O)C(C)(C)CO)=O QHOREGFPJWHMCU-HFEGYEGKSA-N 0.000 description 2
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
- FBPFZTCFMRRESA-NQAPHZHOSA-N Sorbitol Chemical compound OCC(O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-NQAPHZHOSA-N 0.000 description 2
- 102100029677 Trehalase Human genes 0.000 description 2
- 108010087472 Trehalase Proteins 0.000 description 2
- 239000008272 agar Substances 0.000 description 2
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 2
- 229960003957 dexamethasone Drugs 0.000 description 2
- 239000002158 endotoxin Substances 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 229920006008 lipopolysaccharide Polymers 0.000 description 2
- 229960003966 nicotinamide Drugs 0.000 description 2
- 235000005152 nicotinamide Nutrition 0.000 description 2
- 239000011570 nicotinamide Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000000770 proinflammatory effect Effects 0.000 description 2
- 238000003753 real-time PCR Methods 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 1
- 241001474374 Blennius Species 0.000 description 1
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 description 1
- 208000003322 Coinfection Diseases 0.000 description 1
- 108020004635 Complementary DNA Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 102000004388 Interleukin-4 Human genes 0.000 description 1
- 108090000978 Interleukin-4 Proteins 0.000 description 1
- 239000004909 Moisturizer Substances 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 241000015728 Taxus canadensis Species 0.000 description 1
- 229930003571 Vitamin B5 Natural products 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 238000010804 cDNA synthesis Methods 0.000 description 1
- 229960002079 calcium pantothenate Drugs 0.000 description 1
- 230000001914 calming effect Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000005757 colony formation Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 230000008260 defense mechanism Effects 0.000 description 1
- XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 210000002969 egg yolk Anatomy 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 238000009499 grossing Methods 0.000 description 1
- 230000009422 growth inhibiting effect Effects 0.000 description 1
- 150000003278 haem Chemical class 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 229940028885 interleukin-4 Drugs 0.000 description 1
- 239000002085 irritant Substances 0.000 description 1
- 231100000021 irritant Toxicity 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000001333 moisturizer Effects 0.000 description 1
- 210000002864 mononuclear phagocyte Anatomy 0.000 description 1
- 231100001083 no cytotoxicity Toxicity 0.000 description 1
- 230000037311 normal skin Effects 0.000 description 1
- 150000002948 pantothenic acids Chemical class 0.000 description 1
- 238000003752 polymerase chain reaction Methods 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 230000011514 reflex Effects 0.000 description 1
- 229920002477 rna polymer Polymers 0.000 description 1
- 229940109850 royal jelly Drugs 0.000 description 1
- 230000008591 skin barrier function Effects 0.000 description 1
- 230000037380 skin damage Effects 0.000 description 1
- 244000005714 skin microbiome Species 0.000 description 1
- 230000036560 skin regeneration Effects 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 210000003556 vascular endothelial cell Anatomy 0.000 description 1
- 235000009492 vitamin B5 Nutrition 0.000 description 1
- 239000011675 vitamin B5 Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/60—Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/34—Alcohols
- A61K8/345—Alcohols containing more than one hydroxy group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
- A61K8/42—Amides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
- A61Q17/005—Antimicrobial preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/005—Preparations for sensitive skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/59—Mixtures
- A61K2800/592—Mixtures of compounds complementing their respective functions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/70—Biological properties of the composition as a whole
- A61K2800/72—Hypo-allergenic
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Birds (AREA)
- Dermatology (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Emergency Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Cosmetics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明涉及单独包含山梨糖醇或包含山梨糖醇和D‑泛醇和/或海藻糖的混合物的化妆品组合物,具体地,涉及单独的山梨糖醇或山梨糖醇和D‑泛醇和/或海藻糖的混合物赋予皮肤刺激缓解及皮肤炎症缓解效果,从而可预防及改善皮肤过敏,并预防红晕及皮肤炎的刺激缓解化妆品组合物。
Description
技术领域
本发明涉及包含山梨糖醇或其混合物作为有效成分的具有皮肤刺激缓解及皮肤炎症缓解效果的化妆品组合物,更详细地,涉及具有单独的山梨糖醇或山梨糖醇和泛醇和/或海藻糖的混合物的皮肤刺激缓解及皮肤炎症缓解抗炎效果的化妆品组合物。
背景技术
皮肤为从外部刺激保护身体,防止来自皮肤内部的水分损失,并维持人体的恒常性的最重要的防线。这种皮肤位于人体的最外层,因而受到多种刺激,因皮肤屏障受损而有可能发生皮肤炎症反应。此时,若初期无法有效控制炎症反应,则有可能恶化为严重的皮肤炎。
炎症(inflammation)是指对于来自人体内、外部的多种刺激的生物组织的防御机制,多种免疫细胞和炎症诱导细胞因子参与其中。肿瘤坏死因子-α(TNF-α,tumor necrosisfactor-α)、白细胞介素-1α(IL-1α,interleukin-1α)、白细胞介素-6(IL-6,interleukin-6)等为代表性的炎症诱导细胞因子。肿瘤坏死因子-α主要在由细菌的细胞膜中的脂多糖类(LPS,lipopolysaccharide)激活的巨噬细胞中形成而分泌,白细胞介素-1α在激活的单核吞噬细胞、上皮细胞、血管内皮细胞中形成,白细胞介素-6在T细胞及巨噬细胞中分泌,具有促炎(pro-inflammatory)或抗炎(anti-inflammatory)功能。并且,激活的巨噬细胞(macrophage)不仅生成炎症诱导细胞因子,还过度生成一氧化氮(NO,nitricoxide)或前列腺素(prostaglandin)E2(PGE2)来使炎症过程进一步激活。为了去除炎症诱导原因及受损的细胞而聚集的免疫细胞分泌多种细胞因子(cytokines),并通过复合生理反应治愈皮肤,此时,出现红斑、浮肿、发热、疼痛等的外在症状。并且,在免疫细胞中分泌的细胞因子除了受损的细胞之外,还作用于周边的正常的皮肤组织及结构物质,从而常引起不愿意出现的皮肤受损。
另一方面,山梨糖醇(sorbitol)作为具有分子量为182.18的6个-OH基的糖醇,广泛地存在于自然界中,尤其,大量包含在水果类、海藻类中。山梨糖醇具有强力吸收水分的性质,从而用作保湿剂、柔软剂、光泽剂等。D-泛醇(D-panthenol)是作为维生素B5的泛酸的衍生物,分布于蜂王浆、卵黄等很多食品中,以皮肤再生及保护、湿润、抗炎目的使用。海藻糖(trehalose)为由2分子葡萄糖组成的二糖类,具有在高的温度和酸性条件下也稳定的特征,在细胞外部形成保护膜,因而用作抗炎及保湿剂。
但是,至今,尚未公知山梨糖醇皮肤抗炎功效及基于山梨糖醇、D-泛醇、海藻糖的混合物的皮肤抗炎协同效果。
发明内容
本发明人为了开发具有皮肤抗炎效果的组合物而锐意研究努力。其结果,对于单独的山梨糖醇或山梨糖醇和D-泛醇和/或海藻糖的混合物而言,参与皮肤炎症的炎症性细胞因子白细胞介素-1α、白细胞介素-6基因表达减少效果优秀,在简易临床评价中查明到镇静因刺激而引起的红斑的效果,从而完成本发明。
因此,本发明的主要目的在于,提供单独包含山梨糖醇或包含山梨糖醇和D-泛醇和/或海藻糖的混合物的抗炎化妆品组合物。
本发明的另一目的在于,提供以单独适用山梨糖醇或适用山梨糖醇、D-泛醇及海藻糖混合物的剂型,赋予皮肤刺激缓解及皮肤炎症缓解效果,从而可预防及改善皮肤过敏,并预防红晕及皮肤炎的刺激缓解化妆品组合物。
根据本发明的一实施方式,本发明提供包含山梨糖醇(sorbitol)作为有效成分的皮肤刺激缓解及皮肤炎症缓解用化妆品组合物。
本发明的特征在于,优选地,还包含选自泛醇(panthenol)或海藻糖(trehalose)中的一种以上作为有效成分,最优选地,包含山梨糖醇、泛醇及海藻糖的混合物作为有效成分。本发明的特征在于,例如,山梨糖醇、D-泛醇及海藻糖能够以1~3:1~3:1~3的重量比进行配合,更优选地,作为山梨糖醇和D-泛醇、海藻糖的组合,以1:1:1进行配合。
根据本发明的实验例,确认到与将上述各个成分单独配合或将2种(D-泛醇、海藻糖)配合时相比,将山梨糖醇作为基体,混合D-泛醇或海藻糖时,皮肤刺激缓解效果更优秀,进而,确认到以1:1配合山梨糖醇和泛醇这2种成分的情况和均以1:1:1配合三种成分的情况下,呈现最优秀的皮肤刺激缓解效果。
本发明的特征在于,上述化妆品组合物缓解皮肤的刺激及改善炎症来呈现抗炎症效果。
根据本发明的实验例,为了确认皮肤的抗炎效果,确认作为炎症性细胞因子的白细胞介素-1α和白细胞介素-6的表达程度,其结果可确认到将各个成分单独处理(处理组1-3)或处理2种(处理组4-6)及处理3种(处理组7)时,均可抑制基因表达,尤其,以1:1:1混合3种成分时,确认到白细胞介素-1α、白细胞介素-6的表达最减少。由这种结果可知,本发明的化妆品组合物减少炎症反应中起到重要作用的炎症性细胞因子的表达,抑制皮肤的炎症反应,由此可呈现抗炎效果。
根据本发明的实验例,确认到不仅呈现通过炎症性细胞因子的表达抑制的皮肤抗炎效果,而且呈现针对作为皮肤常在菌成为病因环境时,作为二次感染源引起皮肤过敏和炎症反应的金黄色葡萄球菌(Staphylococcus aureus)的抗菌效果。
本发明的特征在于,上述化妆品组合物减少皮肤红斑来呈现对于刺激的缓解效果。皮肤刺激的原因非常多样,因多种刺激而最优先出现的症状之一为皮肤的红斑。
根据本发明的实验例,为了确认皮肤刺激缓解的效果,测定皮肤发红,其结果可确认到将各个成分单独处理(处理组1)或处理2种(处理组4-6)及处理3种(处理组7)时,均与无成分的无处理组相比,红斑显著减少,尤其,以1:1混合山梨糖醇和泛醇这2种成分时,确认到最突出地抑制红斑。由这种结果可知,本发明的化妆品组合物可抑制因皮肤刺激而引起的红斑,由此可呈现刺激缓解效果。
本发明的特征在于,上述化妆品组合物为选自由润肤液、柔肤水、爽肤水、收敛剂、护肤液、乳液、保湿乳液、营养乳液、按摩霜、营养霜、保湿霜、护手霜、粉底霜、精华液、营养精华液、面膜、香皂、洗面奶、洁面乳、洁面霜、润肤乳或沐浴露组成的组中的一种以上的剂型。
如上所述,本发明涉及单独包含山梨糖醇或包含山梨糖醇和D-泛醇和/或海藻糖的混合物作为有效成分的皮肤刺激缓解及抗炎症用化妆品组合物,具有因皮肤刺激而增加的红斑缓解效果,并可有效抑制在细胞内超表达的炎症诱导细胞因子(白细胞介素-1α、白细胞介素-6)的表达来缓解皮肤刺激及皮肤炎症。
附图说明
图1为表示炎症诱导细胞因子中白细胞介素-6基因表达抑制程度的实验例4的结果的图。
图2为确认皮肤刺激缓解的实验例5的结果。
具体实施方式
以下,通过实施例更详细说明本发明。这些实施例仅用于例示本发明,故而不被解释为本发明的范围局限于这些实施例。
实施例1:原料的制备
本发明中使用的山梨糖醇(SORBITOL)以干燥增量为基准,将70%的D-山梨糖醇溶解于30%的纯化水而得,作为该山梨糖醇购买D-山梨糖醇液(韩国韩酷(Happy Call)股份公司)来使用。并且,作为D-泛醇(韩国Serochem股份公司)购买100%的D-泛醇(D-PANTHENOL)来使用。并且,作为海藻糖(韩国Shinwoo ICT股份公司)购买100%的海藻糖(TREHALOSE)来使用。
本发明中使用的试样的浓度如下列表1。
表1
实验例1:抗菌效果
为了确认实施例1的原料的抗菌效果,使用金黄色葡萄球菌菌株来测定菌落(colony)形成量。更详细地,对琼脂平板(agar plate)涂布金黄色葡萄球菌,并以0.5%处理实施例1的原料和它们的混合物来培养。计算随后生成的菌落数来求出平均,评价抗菌效果。将其结果示于表2中。
表2
其结果,如上述表2的结果所示,可在用具有抗菌效果的泛醇处理的所有组中确认抗炎效果。但是,即使单独用处理组1的山梨糖醇处理,也可确认突出的金黄色葡萄球菌生长抑制效果。
实验例2:细胞毒性的评价
对于实施例1的原料的细胞毒性,确认正常人角质形成细胞(Normal HumanKeratinocyte)的生存率。更详细地,用0.05%的实施例1的原料和它们的混合物处理正常人角质形成细胞来进行培养,从而使用作为确认细胞毒性的试样的MTT来评价生存率。将其结果示于表3中。
表3
成分 | 细胞生存率(对照组百分比) | |
无处理组 | DW | 100 |
处理组1 | sorbitol(A) | 94.7 |
处理组2 | D-panthenol(B) | 90.9 |
处理组3 | trehalose(C) | 93.8 |
处理组4 | A+B,1:1 | 92.4 |
处理组5 | A+C,1:1 | 85.0 |
处理组6 | B+C,1:1 | 93.2 |
处理组7 | A+B+C,1:1:1 | 85.1 |
其结果,如上述表3的结果所示,确认到没有因山梨糖醇、泛醇及海藻糖原料而引起的细胞毒性。
实验例3:抗炎效果-白细胞介素-1α表达抑制
为了确认实施例1的原料的抗炎症效果,在正常人角质形成细胞中测定炎症诱导细胞因子白细胞介素-1α的表达量。更详细地,用作为刺激诱导物质的十二烷基硫酸钠(SDS,Sodium dodecyl sulfate)来处理正常人角质形成细胞,增加炎症诱导细胞因子白细胞介素-1α的表达量,用0.05%的实施例1的原料和它们的混合物处理来进行培养。接着,在细胞内提取信使核糖核酸(mRNA),合成为互补脱氧核糖核酸(cDNA),并使用靶模板(primer)来实施实时(real-time)聚合酶链式反应(PCR),从而评价白细胞介素-1α表达程度。将其结果示于表4中。
表4
其结果,如上述表4的结果所示,当单独用处理组1的山梨糖醇处理时,白细胞介素-1α的表达抑制效果突出。并且,除了山梨糖醇之外,泛醇、海藻糖原料本身也有白细胞介素-1α的表达抑制效果,但是确认到基于原料混用的协同作用时,在以1:1:1混合3种原料来处理的处理组7中呈现最优秀的表达抑制能力。
实验例4:抗炎效果-白细胞介素-6表达抑制
为了确认实施例1的原料的抗炎症效果,在HaCaT角质形成细胞中测定炎症诱导细胞因子白细胞介素-6的表达量。更详细地,用作为刺激诱导物质的聚肌胞(Poly IC)(10μg/ml)和白细胞介素-4(10ng/ml)来处理HaCaT角质形成细胞(HaCaT Keratinocyte),增加炎症诱导细胞因子白细胞介素-6的表达量,用0.05%的实施例1的原料和它们的混合物处理来进行培养。此时,将1μM的地塞米松(dexamethasone)用作阳性对照物质。接着,在细胞内提取信使核糖核酸,合成为互补脱氧核糖核酸,并使用靶模板(primer)来实施实时(real-time)聚合酶链式反应,从而评价白细胞介素-6表达程度。将其结果示于图1中。
其结果,如上述图1的结果所示,在所有处理组中,白细胞介素-6的表达抑制效果突出。并且,除了山梨糖醇之外,泛醇、海藻糖原料本身也有白细胞介素-6的表达抑制效果,但是确认到基于原料混用的协同作用时,在以1:1:1混合3种原料来处理的处理组7和混合山梨糖醇和泛醇的处理组4中呈现最优秀的表达抑制能力。
处方例1:精华液
为了确认单独的山梨糖醇或山梨糖醇、泛醇、海藻糖的混合物的刺激缓解功效,根据下列表5所示的组成成分及组成比,通过常规的方法进行制备。
表5
实验例5:皮肤刺激缓解效果
为了了解本发明的单独包含山梨糖醇或包含山梨糖醇、D-泛醇及海藻糖混合物原料的化妆品的皮肤刺激缓解效果,实施如下实验。将5名健康的成人作为对象,将上述处方例1的精华液各8ul均匀地涂布于试验部位(2cm×2cm),使其吸收,经过10分钟之后,用作为皮肤刺激源的烟酰胺(niacinamide)来处理。利用黑色素和血红素测定仪(MexameterMX18)(Courage and Khazaka,德国(Germany))分别测定3次刚涂完产品之后、15分钟之后、30分钟之后的皮肤红斑度。
由其结果确认到如下内容,如图2所示,相比于涂布未放入试样的精华液的无处理组,在涂布放入试样的精华液的所有组(处理组1~7)中红斑减少。
Claims (6)
1.一种皮肤刺激缓解及皮肤炎症缓解两用化妆品组合物,其特征在于,包含山梨糖醇作为有效成分。
2.根据权利要求1所述的皮肤刺激缓解及皮肤炎症缓解两用化妆品组合物,其特征在于,还包含选自泛醇或海藻糖中的一种以上作为有效成分。
3.根据权利要求1所述的皮肤刺激缓解及皮肤炎症缓解两用化妆品组合物,其特征在于,所述组合物呈现镇静因皮肤刺激而引起的红斑的效果。
4.根据权利要求1所述的皮肤刺激缓解及皮肤炎症缓解两用化妆品组合物,其特征在于,所述组合物呈现抑制作为炎症性细胞因子的白细胞介素-1α、白细胞介素-6的表达的效果。
5.根据权利要求1所述的皮肤刺激缓解及皮肤炎症缓解两用化妆品组合物,其特征在于,所述组合物还呈现抗菌效果。
6.根据权利要求1所述的皮肤刺激缓解及皮肤炎症缓解两用化妆品组合物,其特征在于,其为选自由润肤液、柔肤水、爽肤水、收敛剂、护肤液、乳液、保湿乳液、营养乳液、按摩霜、营养霜、保湿霜、护手霜、粉底、精华液、营养精华液、面膜、香皂、洗面奶、洁面乳、洁面霜、润肤乳或沐浴露组成的组中的一种以上的剂型。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020190106127A KR102200213B1 (ko) | 2019-08-28 | 2019-08-28 | 솔비톨 또는 그 혼합물을 유효성분으로서 함유하는 피부자극완화 및 피부염증완화용 화장료 조성물 |
KR10-2019-0106127 | 2019-08-28 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN112438903A true CN112438903A (zh) | 2021-03-05 |
Family
ID=74129251
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202010331275.9A Pending CN112438903A (zh) | 2019-08-28 | 2020-04-24 | 包含山梨糖醇或其混合物作为有效成分的皮肤刺激缓解及皮肤炎症缓解用化妆品组合物 |
Country Status (2)
Country | Link |
---|---|
KR (1) | KR102200213B1 (zh) |
CN (1) | CN112438903A (zh) |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH06128136A (ja) * | 1992-06-04 | 1994-05-10 | Shiseido Co Ltd | 皮膚外用剤 |
US6436429B1 (en) * | 1999-06-28 | 2002-08-20 | Gholam A. Peyman | Process and composition for temporarily suppressing pain |
CN1761450A (zh) * | 2003-02-13 | 2006-04-19 | 株式会社林原生物化学研究所 | 特征在于含有α,α-海藻糖的糖类衍生物的皮肤外用剂 |
JP2006335676A (ja) * | 2005-06-01 | 2006-12-14 | Ikeda Mohandou:Kk | 皮膚外用剤 |
KR20130092172A (ko) * | 2012-02-10 | 2013-08-20 | 한국콜마주식회사 | 폴리올 및 유화제를 포함하는 저 자극 및 고 보습성 수중유형 화장료 조성물 및 그 제조방법 |
CN105616229A (zh) * | 2014-10-31 | 2016-06-01 | 郁丁丁 | 一种具有抗敏功能的乳液 |
CN105902461A (zh) * | 2016-05-11 | 2016-08-31 | 广州智媛生物科技有限公司 | 一种含蜗牛粘液提取物的精华液及其制备方法 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7301016B2 (en) * | 2000-03-07 | 2007-11-27 | Millennium Pharmaceuticals, Inc. | Human transferase family members and uses thereof |
US20180071190A1 (en) * | 2015-03-25 | 2018-03-15 | Gct Gmbh | Cosmetic product and concentrate for producing the cosmetic product |
CN107456438A (zh) * | 2016-06-02 | 2017-12-12 | 玫琳凯有限公司 | 化妆品组合物 |
-
2019
- 2019-08-28 KR KR1020190106127A patent/KR102200213B1/ko active IP Right Grant
-
2020
- 2020-04-24 CN CN202010331275.9A patent/CN112438903A/zh active Pending
Patent Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH06128136A (ja) * | 1992-06-04 | 1994-05-10 | Shiseido Co Ltd | 皮膚外用剤 |
US6436429B1 (en) * | 1999-06-28 | 2002-08-20 | Gholam A. Peyman | Process and composition for temporarily suppressing pain |
CN1761450A (zh) * | 2003-02-13 | 2006-04-19 | 株式会社林原生物化学研究所 | 特征在于含有α,α-海藻糖的糖类衍生物的皮肤外用剂 |
US20070003502A1 (en) * | 2003-02-13 | 2007-01-04 | Fujimi Tanabe | Skin preparation for external use characterized by containing sugar derivative of alpha, alpha-trehalose |
JP2006335676A (ja) * | 2005-06-01 | 2006-12-14 | Ikeda Mohandou:Kk | 皮膚外用剤 |
KR20130092172A (ko) * | 2012-02-10 | 2013-08-20 | 한국콜마주식회사 | 폴리올 및 유화제를 포함하는 저 자극 및 고 보습성 수중유형 화장료 조성물 및 그 제조방법 |
CN105616229A (zh) * | 2014-10-31 | 2016-06-01 | 郁丁丁 | 一种具有抗敏功能的乳液 |
CN105902461A (zh) * | 2016-05-11 | 2016-08-31 | 广州智媛生物科技有限公司 | 一种含蜗牛粘液提取物的精华液及其制备方法 |
Non-Patent Citations (1)
Title |
---|
王正坤, 化学工业出版社 * |
Also Published As
Publication number | Publication date |
---|---|
KR102200213B1 (ko) | 2021-01-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20150017227A1 (en) | Methods and Compositions for Treating Skin Diseases and Conditions | |
WO2008140200A1 (en) | External compositions for the skin | |
CN110638727B (zh) | 一种婴幼儿护臀组合物及其制备方法和应用 | |
CN107998028A (zh) | 一种沐浴露及其制备方法 | |
CN109091433A (zh) | 一种控油祛痘的组合物及其在化妆品中的应用 | |
CA2882392C (en) | Antiseptic, antiseborrheic and exfoliating composition to remove or prevent acne | |
TWI813986B (zh) | 包含半乳寡醣或半乳寡醣和膠原蛋白三肽以改善免疫功能及皮膚狀況的功能性食品組合物和化妝品組合物 | |
CN110025538B (zh) | 一种改善皮肤痤疮、炎症的组合物及其应用 | |
CN112438903A (zh) | 包含山梨糖醇或其混合物作为有效成分的皮肤刺激缓解及皮肤炎症缓解用化妆品组合物 | |
KR20060106554A (ko) | 아토피 피부의 개선 효과를 갖는 애기수영 및/또는 대황추출물 함유 화장료 조성물 | |
US9486397B2 (en) | Dermocosmetic compositions based on a synergistic combination of colloidal silver and deoxyribonucleic acid | |
KR101936686B1 (ko) | 미세 버블을 함유하는 피부 외용제 조성물 | |
KR20080044948A (ko) | 선학초로부터 유효성분의 추출ㆍ정제방법 및 그 추출물을함유한 여드름 예방 및 치료용 생약 조성물 | |
CN114746077A (zh) | 个人护理组合物及用于其的方法 | |
KR20150116504A (ko) | 티트리 추출물 및 소금을 포함하는 화장료 조성물 | |
CN110731956A (zh) | 治疗痤疮、脂溢性皮炎的药物及其制备方法 | |
KR101955100B1 (ko) | 항여드름 활성을 갖는 화장료 조성물 | |
KR20200063798A (ko) | 퀘르세틴, 제니스테인 및 알파리포산을 함유하는 여드름 피부 개선용 조성물 | |
KR102471051B1 (ko) | 천연 소재를 이용한 홍조 및 아토피 예방 및 완화용 조성물 및 이를 포함하는 화장료 | |
WO2022045261A1 (ja) | Cd39遺伝子の発現低下の抑制剤 | |
KR102082580B1 (ko) | 죽여 추출물의 안정화 방법 및 안정화된 죽여 추출물을 함유하는 화장료 조성물 | |
KR20240040207A (ko) | 고농도의 유효성분을 함유하는 피부자극 완화용 유효성분 복합체 및 이의 제조방법 | |
KR20220113587A (ko) | 카르니틴, 아르기닌, 크레아틴, 및 비타민 c 를 유효성분으로 함유하는 화장료 조성물 및 약학적 조성물 | |
CN114845698A (zh) | 多效个人护理组合物和其方法 | |
KR102611502B1 (ko) | 클로로젠산을 포함하는 피부 노화 방지용 피부외용제 조성물 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
WD01 | Invention patent application deemed withdrawn after publication | ||
WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20210305 |